Talented team and industry-leading lab will help strengthen the company’s sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings.
The Flinn Foundation hosted its annual bioscience event April 14 to share the impressive progress of Arizona’s growing sector nearly two decades since the launch of Arizona’s Bioscience Roadmap.
The virtual event featured a keynote address by Tom Osha of Wexford Science and Technology and a mix of live presentations and videos showcasing the innovative and growing bioscience ecosystem throughout Arizona, including Flagstaff, metro Phoenix, and the Tucson and Yuma regions. Continue reading
Applications for the 2021 FCC Telehealth Program are expected to open soon. Life365 is providing information and resources to help qualified healthcare organizations get started with their applications.
Boosting ABCC1 could lessen the production of plaque linked to Alzheimer’s development
PHOENIX, Ariz. — April 13, 2021 — Findings of a study by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that increasing expression of a gene known as ABCC1 could not only reduce the deposition of a hard plaque in the brain that leads to Alzheimer’s disease, but might also prevent or delay this memory-robbing disease from developing.
The Arizona Health Care Cost Containment System (AHCCCS), in partnership with Crisis Response Network, announces a new COVID-19 appointment and transportation navigation program for Medicaid members. Now, Medicaid members who need assistance scheduling a COVID-19 vaccine appointment, as well as transportation to and from that appointment, can call 1-844-542-8201, 8 a.m. to 5 p.m., seven days a week.Continue reading
New patient-level data will facilitate more efficient clinical trial design
OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity
vMYX-hIL-12/Dec produces functional protein (hIL-12) from transgenes in vivo and in a dose and time responsive in vitro and has demonstrated anti-tumor efficacy in a xenograft human lung cancer model
Quantitative systems pharmacology modeling suggests IV administration of multi-armed myxoma virotherapy to fall within known safety margins at the planned doses of oncolytic immunotherapiesContinue reading